Komori
Share Issuance and Disposal4598Delta-Fly Pharma,Inc.Pharmaceuticals

Notice Regarding the Monthly Exercise Status of the 11th Series of Stock Acquisition Rights (Stock Acquisition Rights with Provisions for Adjustment of the Exercise Price)

In March 2026, 2,000 of the 11th Stock Acquisition Rights were exercised, and 200,000 new shares were issued. The unexercised balance at month-end was 19,849 rights.

Worth reading
63In focus
Scored from 2 of 5 sections
Direction
Deterioration
Direction inferred from the company’s description.
Scale
200000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Exercise status report for stock acquisition rights with an exercise price adjustment clause

Who receives how much

Shares issued during the month: 200,000 shares (new shares: 200,000 shares; treasury shares transferred: 0 shares)

Macquarie Bank Limited (the allottee of the previously issued 11th Stock Acquisition Rights)

The lower thin line represents the existing number of shares to which these shares will be added.

Existing Shares and Increase
+2.43%Rate of increase
12,975,000 shares13,175,000Shares

Exercise ratio subject to the exercise restriction: 2.43% (200,000 shares issued across all series / 8,229,900 listed shares outstanding as of the payment date for the issuance)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
Subject to an exercise price adjustment clause. The exercise prices during the relevant month were ¥200, ¥209, ¥213 and ¥186. The adjustment floor is Not disclosed
Number of Stock Acquisition Rights
Total number issued: 30,000 rights (2,000 rights, or 6.67% of the total number issued); unexercised at the end of the preceding month: 21,849 rights; unexercised at the end of the relevant month: 19,849 rights
Procedures under the Corporate Code of Conduct
Describes compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments, etc.
Most recent equity financing
Timing 2 February 2026 / Type 11th Stock Acquisition Rights (Stock Acquisition Rights with Exercise Price Adjustment Clause) / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalExercise status report for stock acquisition rights with an exercise price adjustment clause
Number of shares to be issued or disposed ofShares issued during the month: 200,000 shares (new shares: 200,000 shares; treasury shares transferred: 0 shares)
Intended allotteeMacquarie Bank Limited (the allottee of the previously issued 11th Stock Acquisition Rights)
Dilution RateExercise ratio subject to the exercise restriction: 2.43% (200,000 shares issued across all series / 8,229,900 listed shares outstanding as of the payment date for the issuance)
Total number of issued shares12,975,000 shares (as of the end of the month preceding the relevant month) → 13,175,000 shares (as of the end of the relevant month, calculated)
Exercise priceSubject to an exercise price adjustment clause. The exercise prices during the relevant month were ¥200, ¥209, ¥213 and ¥186. The adjustment floor is Not disclosed
Number of Stock Acquisition RightsTotal number issued: 30,000 rights (2,000 rights, or 6.67% of the total number issued); unexercised at the end of the preceding month: 21,849 rights; unexercised at the end of the relevant month: 19,849 rights
Procedures under the Corporate Code of ConductDescribes compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments, etc.
Most recent equity financingTiming 2 February 2026 / Type 11th Stock Acquisition Rights (Stock Acquisition Rights with Exercise Price Adjustment Clause) / Amount Not disclosed
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the monthly exercise status of the 11th Stock Acquisition Rights in March 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Monthly Exercise Status of the 11th Series of Stock Acquisition Rights (Stock Acquisition Rights with Provisions for Adjustment of the Exercise Price) | Delta-Fly Pharma,Inc. (4598) timely disclosure | Komori